Pipeline
Fueled by a deep scientific understanding built over decades of neuroscience research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab, PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau and TDP-43 where our scientific understanding of disease pathology can be leveraged.
Prasinezumab is currently in a Phase 2 study in patients with early Parkinson’s disease. PRX004 is currently in a Phase 1 study in patients with ATTR amyloidosis.
Tau
AD, PSP, FTD, CTE
TDP-43
ALS, FTD
Undisclosed
Neurodegeneration
